Extracorporeal Membrane Oxygenation System Is Designed for Use over Days or Weeks to Help the Child’s Body Rest and Recover from Severe Heart and Lung Disease
Extracorporeal Membrane Oxygenation System (ECMO) is an advanced life support technology that acts as the child's heart and lungs when they cannot work correctly, like during surgery or disease. With ECMO, the heart and lungs can "rest" for days to weeks to allow recovery This advanced technology is a type of heart-lung bypass machine, similar to the ones used during open heart surgery that pumps blood rich in oxygen and delivers it to the whole body through an artificial lung. The heart and lungs continue to work normally, with an external mechanical support, delivering blood flow and oxygen to the patient's organs.
Awake Extracorporeal Membrane Oxygenation System is a life-saving therapy that enables patients with severe cardiac and/or pulmonary failure to recover and be discharged from the intensive care unit (ICU) sooner. It gives clinicians the time they need to treat and diagnose the underlying cause of their illness, while ensuring gas exchange and end-organ perfusion. The initiation of ECMO is associated with an immediate and complex inflammatory response that may be a leading cause of adverse events in critically ill patients, including cardiogenic shock, acute respiratory distress syndrome or septic shock. The response involves activation of coagulation and complement systems, which can result in leukocyte activation and disrupted microcirculation.
Global Extracorporeal Membrane Oxygenation System Market is estimated to be valued at US$ 316.5 million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030).
This is due to the presence of foreign material, namely the membrane and tubing, in contact with the patient's blood. At the point when blood first touches these surfaces, the innate immune system activates the contact and complement pathways, which can lead to a cascade of activation that may be toxic to cells, leading to damage of the microvascular beds and end-organ dysfunction For more than 50 years, ECMO has been an important tool for the treatment of heart and lung disease. It is also widely used as a temporary bridge to transplant for patients who have exhausted other options, and it can be lifesaving in cases of severe respiratory distress, such as ARDS.
Extracorporeal Membrane Oxygenation System is a complex and specialized system that uses a combination of technologies to support the child’s body. LivaNova PLC., acquired ALung Technologies, Inc., in May 2022. This acquisition was done after the company gained approval from the US FDA for marketing the Hemolung Respiratory Assist System, their artificial lung system.
Comments
Post a Comment